Overview

Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416

Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and exposure of repeat escalating oral doses, a loading dose/maintenance dose regimen of GSK580416 and when co administered with ketoconazole, a PGP/CYP3A4 inhibitor.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Ketoconazole